Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.
Pivot X, Spano JP, Espie M, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Mouri Z, Tariket F, Dupin J, Berthois A, Ionescu-Goga M, Ferhat A, Cottu P, Gligorov J. Pivot X, et al. Among authors: extra jm. Clin Breast Cancer. 2023 Oct;23(7):e412-e419. doi: 10.1016/j.clbc.2023.06.007. Epub 2023 Jun 20. Clin Breast Cancer. 2023. PMID: 37423801
Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised MetaspHer study.
Pivot X, Spano JP, Espie M, Cottu P, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Attar-Rabia H, Benkanoun C, Dima-Martinez L, Esposito N, Gligorov J. Pivot X, et al. Among authors: extra jm. Eur J Cancer. 2017 Sep;82:230-236. doi: 10.1016/j.ejca.2017.05.009. Epub 2017 Jun 23. Eur J Cancer. 2017. PMID: 28648618 Clinical Trial.
High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
Cottu PH, Extra JM, Espie M, Marolleau JP, de Roquancourt A, Makke J, Miclea JM, Laurence V, Mayeur D, Lerebours F, Cuvier C, Marty M. Cottu PH, et al. Among authors: extra jm. Br J Cancer. 2001 Nov 2;85(9):1240-6. doi: 10.1054/bjoc.2001.2069. Br J Cancer. 2001. PMID: 11720455 Free PMC article. Clinical Trial.
[Clinical activity spectrum of irinotecan].
Cottu PH, Extra JM, Lerebours F, Espie M, Marty M. Cottu PH, et al. Among authors: extra jm. Bull Cancer. 1998 Dec;Spec No:21-5. Bull Cancer. 1998. PMID: 9932080 Free article. Review. French.
Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer.
Sabatier R, Diéras V, Pivot X, Brain E, Roché H, Extra JM, Monneur A, Provansal M, Tarpin C, Bertucci F, Viens P, Zemmour C, Gonçalves A. Sabatier R, et al. Among authors: extra jm. Cancer Res Treat. 2018 Oct;50(4):1226-1237. doi: 10.4143/crt.2017.446. Epub 2017 Dec 28. Cancer Res Treat. 2018. PMID: 29281873 Free PMC article.
126 results